Barclays’s Longboard Pharmaceuticals, Inc. Common Stock LBPH Stock Holding History

Barclays’s Portfolio LBPH Stock Details LBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-61,806	Closed	-$2.06M	–	5601
2024 Q3	$2.06M	Buy	61,806 +38,669	+167%	+$1.33M	﹤0.01%	2822
2024 Q2	$625K	Sell	23,137 -6,457	-22%	-$127K	﹤0.01%	2902
2024 Q1	$639K	Buy	29,594 +8,173	+38%	+$178K	﹤0.01%	3443
2023 Q4	$129K	Buy	21,421 +18,634	+669%	+$92.9K	﹤0.01%	4569
2023 Q3	$15.5K	Sell	2,787 -337	-11%	-$2.17K	﹤0.01%	4225
2023 Q2	$22.9K	Buy	+3,124	New	+$23.6K	﹤0.01%	4109

Barclays's LBPH Position: Q4 2024 in Review

Barclays sold out of Longboard Pharmaceuticals, Inc. Common Stock (LBPH) in Q4 2024, closing a stake of 61,806 shares — an estimated $2.06M sold.

Barclays first reported a position in LBPH in Q2 2023 and held it in 6 quarters. The position peaked at $2.06M in Q3 2024. 0 funds tracked by Wall St. Rank hold LBPH as of Q4 2024.

Barclays reported no remaining Longboard Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
Barclays sold 61,806 Longboard Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $2.06M.
Barclays first reported a position in Longboard Pharmaceuticals, Inc. Common Stock in Q2 2023 and held it in 6 quarters.
Barclays's Longboard Pharmaceuticals, Inc. Common Stock position peaked at $2.06M in Q3 2024.
0 funds tracked by Wall St. Rank held Longboard Pharmaceuticals, Inc. Common Stock as of Q4 2024.

Based on Barclays's 13F filing for Q4 2024, filed 13 Feb 2025.